Why Truly Personalized Medicine Is Oncology's Next Big Frontier
Dr. Joyce Ohm discusses the future of oncology, emphasizing the shift toward truly personalized medicine based on a patient's unique tumor biology. She notes that while identifying actionable mutations is a major step forward, the field still faces challenges in developing targeted therapies and scaling the necessary infrastructure.
Why it matters
Personalized medicine represents a paradigm shift in cancer treatment, moving away from generalized protocols toward highly effective, patient-specific interventions.
This is part 4 of an interview. Watch part 1, part 2, and part 3.
In the final segment of the interview, Joyce Ohm, PhD, looks ahead to what she sees as the next major frontier in oncology: truly personalized medicine. She emphasizes that every patient's tumor is biologically unique, and the ultimate goal of the field is to identify the single best treatment for each individual patient's specific disease, rather than relying on one-size-fits-all approaches.
Ohm notes that meaningful progress is already underway. The identification of "actionable mutations"—genetic changes with known clinical significance—now allows physicians to make more informed treatment decisions, choosing between therapies based on the molecular characteristics of a patient's tumor rather than general disease categories alone. This represents a significant step beyond traditional, broadly applied cancer treatments.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in